Published On : August 2020 Pages : 150 Category: Pharma & Healthcare Report Code : HC0812321
Glp-1 Receptor Agonist Market by Type (Victoza, Ozempic, Saxenda, Trulicity, Bydureon, Other) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Glp-1 Receptor Agonist Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Glp-1 Receptor Agonist are the drugs for Type- 2 Diabetes, they act on hormones called incretins and causes the pancreas to produce more insulin after eating and helps keep blood glucose levels in the normal range.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
Some of the key questions answered by the report are:
a
Market Classification
· Glp-1 Receptor Agonist Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Victoza
o Ozempic
o Saxenda
o Trulicity
o Bydureon
o Other
· Glp-1 Receptor Agonist Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Eli Lilly and Company
o Sanofi
o Novo Nordisk A/S
o AstraZeneca
· Glp-1 Receptor Agonist Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Glp-1 Receptor Agonist Market, By Country
o U.S. Glp-1 Receptor Agonist Market
o Canada Glp-1 Receptor Agonist Market
o Mexico Glp-1 Receptor Agonist Market
o Europe
§ Europe Glp-1 Receptor Agonist Market, By Country
o Germany Glp-1 Receptor Agonist Market
o UK Glp-1 Receptor Agonist Market
o France Glp-1 Receptor Agonist Market
o Russia Glp-1 Receptor Agonist Market
o Italy Glp-1 Receptor Agonist Market
o Rest of Europe Glp-1 Receptor Agonist Market
o Asia-Pacific
§ Asia-Pacific Glp-1 Receptor Agonist Market, By Country
o China Glp-1 Receptor Agonist Market
o Japan Glp-1 Receptor Agonist Market
o South Korea Glp-1 Receptor Agonist Market
o India Glp-1 Receptor Agonist Market
o Southeast Asia Glp-1 Receptor Agonist Market
o Rest of Asia-Pacific Glp-1 Receptor Agonist Market
o South America
§ South America Glp-1 Receptor Agonist Market, By Country
o Brazil Glp-1 Receptor Agonist Market
o Argentina Glp-1 Receptor Agonist Market
o Columbia Glp-1 Receptor Agonist Market
o Rest of South America Glp-1 Receptor Agonist Market
o Middle East and Africa
§ Middle East and Africa Glp-1 Receptor Agonist Market, By Country
o Saudi Arabia Glp-1 Receptor Agonist Market
o UAE Glp-1 Receptor Agonist Market
o Egypt Glp-1 Receptor Agonist Market
o Nigeria Glp-1 Receptor Agonist Market
o South Africa Glp-1 Receptor Agonist Market
o Rest of MEA Glp-1 Receptor Agonist Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Glp-1 Receptor Agonist Market, By Type
5.1. Introduction
5.2. Global Glp-1 Receptor Agonist Revenue and Market Share by Type (2017-2021)
5.2.1. Global Glp-1 Receptor Agonist Revenue and Revenue Share by Type (2017-2021)
5.3. Victoza
5.3.1. Global Victoza Revenue and Growth Rate (2017-2021)
5.4. Ozempic
5.4.1. Global Ozempic Revenue and Growth Rate (2017-2021)
5.5. Saxenda
5.5.1. Global Saxenda Revenue and Growth Rate (2017-2021)
5.6. Trulicity
5.6.1. Global Trulicity Revenue and Growth Rate (2017-2021)
5.7. Bydureon
5.7.1. Global Bydureon Revenue and Growth Rate (2017-2021)
5.8. Other
5.8.1. Global Other Revenue and Growth Rate (2017-2021)
6. Glp-1 Receptor Agonist Market, By Region
6.1. Introduction
6.2. Global Glp-1 Receptor Agonist Revenue and Market Share by Regions
6.2.1. Global Glp-1 Receptor Agonist Revenue by Regions (2017-2021)
6.3. North America Glp-1 Receptor Agonist by Countries
6.3.1. North America Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2021)
6.3.2. North America Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2021)
6.3.3. United States
6.3.3.1. United States Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.4. Canada
6.3.4.1. Canada Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.5. Mexico
6.3.5.1. Mexico Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.4. Europe Glp-1 Receptor Agonist by Countries
6.4.1. Europe Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2021)
6.4.2. Europe Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2021)
6.4.3. Germany
6.4.3.1. Germany Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.4. France
6.4.4.1. France Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.5. UK
6.4.5.1. UK Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.6. Russia
6.4.6.1. Russia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.7. Italy
6.4.7.1. Italy Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.5. Asia-Pacific Glp-1 Receptor Agonist by Countries
6.5.1. Asia-Pacific Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2021)
6.5.2. Asia-Pacific Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2021)
6.5.3. China
6.5.3.1. China Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.4. Japan
6.5.4.1. Japan Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.5. Korea
6.5.5.1. Korea Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.6. India
6.5.6.1. India Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.6. South America Glp-1 Receptor Agonist by Countries
6.6.1. South America Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2021)
6.6.2. South America Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2021)
6.6.3. Brazil
6.6.3.1. Brazil Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.4. Argentina
6.6.4.1. Argentina Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.5. Columbia
6.6.5.1. Columbia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7. Middle East and Africa Glp-1 Receptor Agonist by Countries
6.7.1. Middle East and Africa Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2021)
6.7.2. Middle East and Africa Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2021)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.5. Egypt
6.7.5.1. Egypt Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.6. Nigeria
6.7.6.1. Nigeria Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.7. South Africa
6.7.7.1. South Africa Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.8. Turkey
6.7.8.1. Turkey Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2021)
7. Company Profiles
7.1. Eli Lilly and Company
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Sanofi
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Novo Nordisk A/S
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. AstraZeneca
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
8. Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.1. Global Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2022-2027)
8.2. Glp-1 Receptor Agonist Market Forecast by Regions (2022-2027)
8.2.1. North America Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.1.1. United States Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.1.2. Canada Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.1.3. Mexico Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2. Europe Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2.1. Germany Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2.2. France Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2.3. UK Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2.4. Russia Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2.5. Italy Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.2.6. Rest of Europe Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3. Asia-Pacific Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3.1. China Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3.2. Japan Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3.3. Korea Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3.4. India Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3.5. Southeast Asia Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.3.6. Rest of Asia-Pacific Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.4. South America Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.4.1. Brazil Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.4.2. Argentina Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.4.3. Columbia Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.4.4. Rest of South America Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5. Middle East and Africa Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.1. Saudi Arabia Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.2. United Arab Emirates Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.3. Egypt Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.4. Nigeria Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.5. South Africa Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.6. Turkey Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.2.5.7. Rest of Middle East and Africa Glp-1 Receptor Agonist Market Forecast (2022-2027)
8.3. Glp-1 Receptor Agonist Market Forecast by Type (2022-2027)
8.3.1. Glp-1 Receptor Agonist Forecast by Type (2022-2027)
8.3.2. Glp-1 Receptor Agonist Market Share Forecast by Type (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Glp-1 Receptor Agonist Revenue and Revenue Share by Type (2017-2019)
Figure Global Victoza Revenue and Growth Rate (2017-2019)
Figure Global Ozempic Revenue and Growth Rate (2017-2019)
Figure Global Saxenda Revenue and Growth Rate (2017-2019)
Figure Global Trulicity Revenue and Growth Rate (2017-2019)
Figure Global Bydureon Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Glp-1 Receptor Agonist Revenue by Regions (2017-2019)
Figure North America Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure North America Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure North America Glp-1 Receptor Agonist by Countries (2017-2019)
Figure North America Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure United States Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure United States Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Canada Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Mexico Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Europe Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure Europe Glp-1 Receptor Agonist by Countries (2017-2019)
Figure Europe Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure Germany Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Germany Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure France Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure UK Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Russia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Italy Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of Europe Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist by Countries (2017-2019)
Figure Asia-Pacific Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure China Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure China Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Japan Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Korea Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure India Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Southeast Asia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure South America Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure South America Glp-1 Receptor Agonist by Countries (2017-2019)
Figure South America Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Brazil Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Argentina Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Columbia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of South America Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist by Countries (2017-2019)
Figure Middle East and Africa Glp-1 Receptor Agonist Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Saudi Arabia Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure United Arab Emirates Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Egypt Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Nigeria Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure South Africa Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Turkey Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2017-2019)
Table Eli Lilly and Company Glp-1 Receptor Agonist Financial Overview
Table Sanofi Glp-1 Receptor Agonist Financial Overview
Table Novo Nordisk A/S Glp-1 Receptor Agonist Financial Overview
Table AstraZeneca Glp-1 Receptor Agonist Financial Overview
Figure Global Glp-1 Receptor Agonist Revenue (Millions USD) and Growth Rate (2019-2027)
Table Glp-1 Receptor Agonist Market Forecast by Regions (2019-2027)
Figure North America Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure United States Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Canada Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Mexico Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Europe Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Germany Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure France Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure UK Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Russia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Italy Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of Europe Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Asia-Pacific Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure China Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Japan Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Korea Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure India Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Southeast Asia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure South America Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Brazil Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Argentina Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Columbia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of South America Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Middle East and Africa Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Saudi Arabia Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure United Arab Emirates Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Egypt Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Nigeria Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure South Africa Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Turkey Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Glp-1 Receptor Agonist Market Forecast (2019-2027)
Figure Global Glp-1 Receptor Agonist Forecast by Type (2019-2027)
Figure Global Glp-1 Receptor Agonist Market Share Forecast by Type (2019-2027)
Figure Global Glp-1 Receptor Agonist Forecast by Type (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
Data Collection Matrix |
Supply Side |
Demand Side |
Primary Data Sources |
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
Qualitative Data |
Quantitative Data (2017-2025) |
|
|